It is now common to observe treatment-resistant tumours with neuroendocrine features upon metastatic biopsy, and the prevailing consensus is that epithelial plasticity enables tumour adaptation in response to AR-targeted therapies [7, 9, 118, 126, 131–134]. This evidence concerns the gene AR and neoplasm.